Medindia

Dexmethylphenidate Hcl Interaction with other Drugs

Dexmethylphenidate Hcl is the dextrorotatory enantiomer of methylphenidate, prescribed for attention deficit hyperactivity disorder (ADHD). Aloglutamol can cause an increase in the absorption of ...
Medindia

Dexmethylphenidate Interaction with Alcohol

Avoid alcohol intake while using Dexmethylphenidate as it can cause side effects like drowsiness, dizziness and impaired concentration (1 Trusted Source National Institute on Alcohol and Alcoholism.
Yahoo Finance

Cingulate Completes First Cohort of Phase 3 Adult Onset and Duration Trial of CTx-1301 (dexmethylphenidate) for ADHD

KANSAS CITY, Kan., April 04, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform ...
Yahoo Finance

Cingulate Announces Successful Transfer of CTx-1301 (dexmethylphenidate) Proprietary PTR™ Manufacturing Processes to Societal CDMO

KANSAS CITY, Kan., May 03, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform ...
Nasdaq

Cingulate Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD

KANSAS CITY, Kan., July 11, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform ...
Medscape

FDA Approves Focalin XR for ADHD

November 21, 2008 — The US Food and Drug Administration has approved dexmethylphenidate HCl extended-release capsules (Focalin XR, Novartis) for the treatment of ...
manilatimes

Efficacy Results Announced from Cingulate's Phase 3 Pediatric Study of CTx-1301 (dexmethylphenidate) for ADHD

KANSAS CITY, Kan., May 20, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform ...
Monthly Prescribing Reference

Novel Dexmethylphenidate Formulation Under Review for ADHD

A Prescription Drug User Fee Act target date of May 31, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ...
Monthly Prescribing Reference

Azstarys, a Once-Daily Treatment for ADHD, Gets FDA Approval

Credit: Getty Images. Azstarys consists of serdexmethylphenidate, a prodrug of dexmethylphenidate, co-formulated with immediate-release dexmethylphenidate. The Food and Drug Administration (FDA) has ...
Stockhouse

Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD

KANSAS CITY, Kan., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform ...
ksn.com

Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD

KANSAS CITY, Kan., June 08, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform ...